Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/24710 |
Resumo: | This article is a narrative review of the literature which aims to describe the main pharmacological aspects of pre-exposure prophylaxis (PrEP) to HIV. The human immunodeficiency virus (HIV) is an infection that has affected people all over the world. However, this number has decreased in recent decades, this is due to the demand for information leading to prevention and adherence to the use of PrEP PrEP is characterized as a prevention strategy that includes the daily and continuous use of antiretroviral drugs, studies show the effectiveness of the combined use of two daily antiretroviral drugs, tenofovir (TDF) and emtricitabine, commercially known as truvada. However, it is extremely important to know and discuss the pharmacological aspects of the drug, and this involves its pharmacokinetics, which in turn includes the mechanisms of absorption, distribution, metabolism and excretion of the drug, as well as other important parameters such as the half-life and elimination time of the drug, and its possible drug interactions, adverse reactions, and its mechanism of action, which is associated with the pharmacodynamic aspects of the drug. |
id |
UNIFEI_3c50fdb02230550fb0c9a9165faef313 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/24710 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a reviewAspectos farmacológicos de la profilaxis previa a la exposición (prep) al VIH: una revisiónAspectos farmacológicos da profilaxia de pré-exposição (prep) ao HIV: revisãoPharmacological aspectsHIVPre-exposure prophylaxisPrEP.Aspectos farmacológicosVIHProfilaxis previa a la exposiciónPrEP.Aspectos farmacológicosHIVProfilaxia pré-exposiçãoPrEP.This article is a narrative review of the literature which aims to describe the main pharmacological aspects of pre-exposure prophylaxis (PrEP) to HIV. The human immunodeficiency virus (HIV) is an infection that has affected people all over the world. However, this number has decreased in recent decades, this is due to the demand for information leading to prevention and adherence to the use of PrEP PrEP is characterized as a prevention strategy that includes the daily and continuous use of antiretroviral drugs, studies show the effectiveness of the combined use of two daily antiretroviral drugs, tenofovir (TDF) and emtricitabine, commercially known as truvada. However, it is extremely important to know and discuss the pharmacological aspects of the drug, and this involves its pharmacokinetics, which in turn includes the mechanisms of absorption, distribution, metabolism and excretion of the drug, as well as other important parameters such as the half-life and elimination time of the drug, and its possible drug interactions, adverse reactions, and its mechanism of action, which is associated with the pharmacodynamic aspects of the drug.Este artículo es el resultado de una revisión bibliográfica narrativa que pretende describir los principales aspectos farmacológicos de la profilaxis preexposición (PPrE) al VIH. El virus de la inmunodeficiencia humana (VIH), es una infección que ha afectado a personas de todo el mundo. Sin embargo, este número ha disminuido en las últimas décadas, esto se debe a la demanda de información que lleva a la prevención y a la adherencia al uso de la PrEP La PrEP se caracteriza por ser una estrategia de prevención que incluye el uso diario y continuo de medicamentos antirretrovirales, los estudios demuestran la eficacia del uso combinado de dos medicamentos antirretrovirales diarios, tenofovir (TDF) y emtricitabina, conocido comercialmente como truvada. Sin embargo, es sumamente importante conocer y discutir los aspectos farmacológicos del fármaco y esto implica su farmacocinética, que a su vez incluye los mecanismos de absorción, distribución, metabolismo y excreción del fármaco, así como otros parámetros importantes como la vida media y el tiempo de eliminación del fármaco, así como sus posibles interacciones farmacológicas, reacciones adversas y su mecanismo de acción, que se asocia con los aspectos farmacodinámicos del fármaco.Este artigo é uma revisão narrativa da literatura que visa descrever os principais aspectos farmacológicos da profilaxia pré-exposição (PrEP) ao VIH. O vírus da imunodeficiência humana (VIH) é uma infecção que tem afetado pessoas em todo o mundo. Contudo, este número diminuiu nas últimas décadas, isto deve-se à procura de informação conducente à prevenção e à adesão ao uso da PrEP PrEP caracteriza-se como uma estratégia de prevenção que inclui o uso diário e contínuo de medicamentos antirretrovirais, estudos mostram a eficácia do uso combinado de dois medicamentos antirretrovirais diários, tenofovir (TDF) e emtricitabina, comercialmente conhecido como truvada. No entanto, é extremamente importante conhecer e discutir os aspectos farmacológicos do fármaco, e isto envolve a sua farmacocinética, que por sua vez inclui os mecanismos de absorção, distribuição, metabolismo e excreção do fármaco, bem como outros parâmetros importantes como o tempo de meia-vida e eliminação do fármaco, e as suas possíveis interações medicamentosas, reações adversas, e o seu mecanismo de ação, que está associado com os aspectos farmacodinâmicos do fármaco.Research, Society and Development2022-07-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2471010.33448/rsd-v11i9.24710Research, Society and Development; Vol. 11 No. 9; e15511924710Research, Society and Development; Vol. 11 Núm. 9; e15511924710Research, Society and Development; v. 11 n. 9; e155119247102525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/24710/27011Copyright (c) 2022 Edson Bruno Campos Paiva; Caroline Rocha da Silveira; Isis de Oliveira Kosmiscky; Cleiton da Costa Gomes ; Samantha Daniely Gomes Barros; Roselígia Antônia da Costa Farias; Zélia de Oliveira Saldanha; Antônio Rafael Quadros Gomes; Cybelle Silva do Couto Coelho; Sabrina de Carvalho Cartágeneshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessPaiva, Edson Bruno Campos Silveira, Caroline Rocha da Kosmiscky, Isis de Oliveira Gomes , Cleiton da CostaBarros, Samantha Daniely Gomes Farias, Roselígia Antônia da Costa Saldanha, Zélia de Oliveira Gomes, Antônio Rafael Quadros Coelho, Cybelle Silva do Couto Cartágenes, Sabrina de Carvalho2022-07-21T12:36:16Zoai:ojs.pkp.sfu.ca:article/24710Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:43:10.753011Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review Aspectos farmacológicos de la profilaxis previa a la exposición (prep) al VIH: una revisión Aspectos farmacológicos da profilaxia de pré-exposição (prep) ao HIV: revisão |
title |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review |
spellingShingle |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review Paiva, Edson Bruno Campos Pharmacological aspects HIV Pre-exposure prophylaxis PrEP. Aspectos farmacológicos VIH Profilaxis previa a la exposición PrEP. Aspectos farmacológicos HIV Profilaxia pré-exposição PrEP. |
title_short |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review |
title_full |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review |
title_fullStr |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review |
title_full_unstemmed |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review |
title_sort |
Pharmacological aspects of prophylaxis pre-exposure (prep) to HIV: a review |
author |
Paiva, Edson Bruno Campos |
author_facet |
Paiva, Edson Bruno Campos Silveira, Caroline Rocha da Kosmiscky, Isis de Oliveira Gomes , Cleiton da Costa Barros, Samantha Daniely Gomes Farias, Roselígia Antônia da Costa Saldanha, Zélia de Oliveira Gomes, Antônio Rafael Quadros Coelho, Cybelle Silva do Couto Cartágenes, Sabrina de Carvalho |
author_role |
author |
author2 |
Silveira, Caroline Rocha da Kosmiscky, Isis de Oliveira Gomes , Cleiton da Costa Barros, Samantha Daniely Gomes Farias, Roselígia Antônia da Costa Saldanha, Zélia de Oliveira Gomes, Antônio Rafael Quadros Coelho, Cybelle Silva do Couto Cartágenes, Sabrina de Carvalho |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Paiva, Edson Bruno Campos Silveira, Caroline Rocha da Kosmiscky, Isis de Oliveira Gomes , Cleiton da Costa Barros, Samantha Daniely Gomes Farias, Roselígia Antônia da Costa Saldanha, Zélia de Oliveira Gomes, Antônio Rafael Quadros Coelho, Cybelle Silva do Couto Cartágenes, Sabrina de Carvalho |
dc.subject.por.fl_str_mv |
Pharmacological aspects HIV Pre-exposure prophylaxis PrEP. Aspectos farmacológicos VIH Profilaxis previa a la exposición PrEP. Aspectos farmacológicos HIV Profilaxia pré-exposição PrEP. |
topic |
Pharmacological aspects HIV Pre-exposure prophylaxis PrEP. Aspectos farmacológicos VIH Profilaxis previa a la exposición PrEP. Aspectos farmacológicos HIV Profilaxia pré-exposição PrEP. |
description |
This article is a narrative review of the literature which aims to describe the main pharmacological aspects of pre-exposure prophylaxis (PrEP) to HIV. The human immunodeficiency virus (HIV) is an infection that has affected people all over the world. However, this number has decreased in recent decades, this is due to the demand for information leading to prevention and adherence to the use of PrEP PrEP is characterized as a prevention strategy that includes the daily and continuous use of antiretroviral drugs, studies show the effectiveness of the combined use of two daily antiretroviral drugs, tenofovir (TDF) and emtricitabine, commercially known as truvada. However, it is extremely important to know and discuss the pharmacological aspects of the drug, and this involves its pharmacokinetics, which in turn includes the mechanisms of absorption, distribution, metabolism and excretion of the drug, as well as other important parameters such as the half-life and elimination time of the drug, and its possible drug interactions, adverse reactions, and its mechanism of action, which is associated with the pharmacodynamic aspects of the drug. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-07-05 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/24710 10.33448/rsd-v11i9.24710 |
url |
https://rsdjournal.org/index.php/rsd/article/view/24710 |
identifier_str_mv |
10.33448/rsd-v11i9.24710 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/24710/27011 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 9; e15511924710 Research, Society and Development; Vol. 11 Núm. 9; e15511924710 Research, Society and Development; v. 11 n. 9; e15511924710 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052791829561344 |